Molecure Valuation

Is MOC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of MOC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate MOC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MOC's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for MOC?

Key metric: As MOC barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for MOC. This is calculated by dividing MOC's market cap by their current book value.
What is MOC's PB Ratio?
PB Ratio	2.2x
Book	zł80.09m
Market Cap	zł173.41m

MOC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	98.8x
Enterprise Value/EBITDA	-5x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does MOC's PB Ratio compare to its peers?

The above table shows the PB ratio for MOC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	4.2x
CBD Cannabis Poland	4.8x	n/a	zł22.6m
BGD Biogened	1.4x	n/a	zł54.0m
CLN Celon Pharma	2.8x	14.4%	zł1.4b
GMT Genomtec	7.7x	n/a	zł98.3m
MOC Molecure	2.2x	11.2%	zł173.4m

Price-To-Book vs Peers: MOC is good value based on its Price-To-Book Ratio (2.2x) compared to the peer average (4.2x).

Price to Book Ratio vs Industry

How does MOC's PB Ratio compare vs other companies in the European Pharmaceuticals Industry?

12 Companies	Price / Book	Estimated Growth	Market Cap

12 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: MOC is good value based on its Price-To-Book Ratio (2.2x) compared to the European Pharmaceuticals industry average (2.4x).

Price to Book Ratio vs Fair Ratio

What is MOC's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

MOC PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.2x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate MOC's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst MOC forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	zł10.30	zł23.25 +125.7%	29.0%	zł30.00	zł16.50	n/a	2
Nov ’25	zł9.85	zł27.80 +182.2%	7.9%	zł30.00	zł25.60	n/a	2
Oct ’25	zł12.70	zł27.80 +118.9%	7.9%	zł30.00	zł25.60	n/a	2
Sep ’25	zł15.08	zł29.80 +97.6%	14.1%	zł34.00	zł25.60	n/a	2
Aug ’25	zł14.92	zł29.80 +99.7%	14.1%	zł34.00	zł25.60	n/a	2
Jul ’25	zł13.54	zł29.80 +120.1%	14.1%	zł34.00	zł25.60	n/a	2
Jun ’25	zł14.92	zł29.80 +99.7%	14.1%	zł34.00	zł25.60	n/a	2

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.